BCR and chronic myelogenous leukemia, BCR-ABL1 positive: While clinical experience of asciminib in CML patients with BCR::ABL1/b3a3 is extremely limited, based on the data presented here and by others [14, 15], asciminib should only be used with extreme caution under close molecular monitoring in this patient population.